How to buy The Joint stock

The Joint Corp is a medical care facilities business based in the US. The Joint shares (JYNT) are listed on the NASDAQ and all prices are listed in US Dollars. The Joint employs 225 staff and has a trailing 12-month revenue of around 0.00.

The Joint share price

Use our graph to track the performance of JYNT stocks over time.

The Joint shares at a glance

• Key figures

Information last updated 2021-04-28.

52-week range	$10.91 - $58.63
50-day moving average	$47.93
200-day moving average	$33.41
Wall St. target price	$52.60
PE ratio	64.1445
Dividend yield	N/A (0%)
Earnings per share (TTM)	$0.90

Buy The Joint shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy The Joint stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of The Joint Corp by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is The Joint under- or over-valued?

Valuing The Joint stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of The Joint's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

The Joint's P/E ratio

The Joint's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 64x. In other words, The Joint shares trade at around 64x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

The Joint's EBITDA

The Joint's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $8.2 million.

The EBITDA is a measure of a The Joint's overall financial performance and is widely used to measure a its profitability.

The Joint financials

Revenue TTM	$58.7 million
Operating margin TTM	9.27%
Gross profit TTM	$52.2 million
Return on assets TTM	6.21%
Return on equity TTM	99.48%
Profit margin	22.44%
Book value	$1.47
Market capitalisation	$823.1 million

TTM: trailing 12 months

Shorting The Joint shares

There are currently 1.1 million The Joint shares held short by investors – that's known as The Joint's "short interest". This figure is 10.6% up from 1.0 million last month.

There are a few different ways that this level of interest in shorting The Joint shares can be evaluated.

The Joint's "short interest ratio" (SIR)

The Joint's "short interest ratio" (SIR) is the quantity of The Joint shares currently shorted divided by the average quantity of The Joint shares traded daily (recently around 147485.47120419). The Joint's SIR currently stands at 7.64. In other words for every 100,000 The Joint shares traded daily on the market, roughly 7640 shares are currently held short.

However The Joint's short interest can also be evaluated against the total number of The Joint shares, or, against the total number of tradable The Joint shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case The Joint's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 The Joint shares in existence, roughly 80 shares are currently held short) or 0.0946% of the tradable shares (for every 100,000 tradable The Joint shares, roughly 95 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against The Joint.

Find out more about how you can short The Joint stock.

The Joint share dividends

We're not expecting The Joint to pay a dividend over the next 12 months.

The Joint share price volatility

Over the last 12 months, The Joint's shares have ranged in value from as little as $10.91 up to $58.63. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while The Joint's is 1.2967. This would suggest that The Joint's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

The Joint overview

The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics in the United States. The company operates through two segments, Corporate Clinics and Franchise Operations. It operates through direct ownership, management arrangements, franchising, and the sale of regional developer rights. As of January 27, 2021, the company operated approximately 550 locations in the United States. The company was incorporated in 2010 and is headquartered in Scottsdale, Arizona. .

Frequently asked questions

• What percentage of The Joint is owned by insiders or institutions?

  Currently 3.386% of The Joint shares are held by insiders and 84.499% by institutions.

• How many people work for The Joint?

  Latest data suggests 225 work at The Joint.

• When does the fiscal year end for The Joint?

  The Joint's fiscal year ends in December.

• Where is The Joint based?

  The Joint's address is: 16767 North Perimeter Drive, Scottsdale, AZ, United States, 85260

• What is The Joint's ISIN number?

  The Joint's international securities identification number is: US47973J1025

• What is The Joint's CUSIP number?

  The Joint's Committee on Uniform Securities Identification Procedures number is: 47973J102